@Article{Bayoglu2015,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="19",
number="5",
year="2015",
title="Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study",
abstract=" Aim of the study : Our aim was to determine the activity and toxicity of uracil/tegafur and leucovorin combination in metastatic colorectal cancer (mCRC) patients who have progressed with all currently active agents.   Material and methods : This study was a retrospective analysis of 50 mCRC patients who had previously failed to respond to all available chemotherapeutics and who received subsequent treatment with uracil/tegafur 250 mg/md1–5 in combination with leucovorin 90 mg/day, d1–5 followed by two days’ rest.    Results:   The median age of the patients was 60 years. Most of them (60%) were male. Bevacizumab was used in 65% and cetuximab in 55% of the patients. Thirty-nine patients (78%) were treated with uracil/tegafur in the fourth line setting. The median treatment duration was 4.2 months (range, 2–24 months). The objective response rate and the disease control rate were 4% and 34%, respectively. Median progression-free survival was 4.1 months (95% CI, 3.6–4.6 months) and overall survival was 6.6 months (95% CI, 4.5–8.6 months). Grade 3 or 4 toxicity was seen in 20% (n = 10) of the patients while 60% (n = 6) of them required dose reductions.    Conclusions : This retrospective data show that uracil/tegafur may be considered in heavily pretreated mCRC patients because of its activity, lower toxicity, and feasibility.",
author="Bayoglu, İbrahim V.
and Yildiz, Ibrahim
and Varol, Umut
and Cokmert, Suna
and AlacacIoğlu, Ahmet
and Kucukzeybek, Yuksel
and Akyol, Murat
and Demir, Lutfiye
and Dirican, Ahmet
and Tarhan, Oktay",
pages="385--390",
doi="10.5114/wo.2015.53374",
url="http://dx.doi.org/10.5114/wo.2015.53374"
}